This is a firm-fixed price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to A&G Pharmaceutical, Inc. (doing business as Precision Antibody). The contract is for the preparation of monoclonal antibodies against the MARCH1 protein, with a ceiling value of $16,900.00 and a performance period through July 31, 2025.
A&G Pharmaceutical is a for-profit manufacturer of biological materials and research services, with a history of federal contracting primarily supporting biomedical research across areas like Alzheimer's disease, malaria, COVID-19, and oncology. The company holds a Blanket Purchase Agreement (BPA) with the NIH Office of Logistics and Acquisition Operations, valued at up to $100 million, which enables it to provide a range of biological materials, laboratory testing, and animal testing services to multiple NIH institutes and the Department of Agriculture's Agricultural Research Service. This specific contract does not have a set-aside designation, indicating open competition.
Generated 3/25/25, 9:44 AM